{"filing":{"accession_number":"0001493152-26-034917","cik":"0001290877","ticker":null,"company_name":"Clinuvel Pharmaceuticals Ltd","form":"6-K","filing_date":"2026-07-28","report_date":"2026-07-28","primary_document":"form6-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1290877/000149315226034917/form6-k.htm"},"events":[{"id":20843,"run_id":18764,"accession_number":"0001493152-26-034917","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This announcement discloses material progress in CLINUVEL's clinical development pipeline for SCENESSE® in vitiligo, including topline results expected in December 2026 from the CUV105 Phase III study (210 patients) and planned initiation of the pivotal CUV107 Phase III study in November 2026 (300 patients). While not a discrete event like an M\u0026A transaction or earnings release, the advancement of a late-stage clinical program with regulatory pathway guidance from the EMA is operationally material to a biopharmaceutical company's prospects and would affect a reasonable investor's assessment of pipeline value and commercialization timeline.","company_name":"Clinuvel Pharmaceuticals Ltd","ticker":null,"filing_date":"2026-07-28","form":"6-K","submitted_at":null,"items":[{"id":20333,"accession_number":"0001493152-26-034917","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This announcement discloses material progress in CLINUVEL's clinical development pipeline for SCENESSE® in vitiligo, including topline results expected in December 2026 from the CUV105 Phase III study (210 patients) and planned initiation of the pivotal CUV107 Phase III study in November 2026 (300 patients). While not a discrete event like an M\u0026A transaction or earnings release, the advancement of a late-stage clinical program with regulatory pathway guidance from the EMA is operationally material to a biopharmaceutical company's prospects and would affect a reasonable investor's assessment of pipeline value and commercialization timeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-28T10:10:35.127917+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":20333,"accession_number":"0001493152-26-034917","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This announcement discloses material progress in CLINUVEL's clinical development pipeline for SCENESSE® in vitiligo, including topline results expected in December 2026 from the CUV105 Phase III study (210 patients) and planned initiation of the pivotal CUV107 Phase III study in November 2026 (300 patients). While not a discrete event like an M\u0026A transaction or earnings release, the advancement of a late-stage clinical program with regulatory pathway guidance from the EMA is operationally material to a biopharmaceutical company's prospects and would affect a reasonable investor's assessment of pipeline value and commercialization timeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-28T10:10:35.127917+00:00","company_name":"Clinuvel Pharmaceuticals Ltd","ticker":null,"filing_date":"2026-07-28"}]}